Prostate cancer following BPH treatments: what the patient should know.

摘要

Despite careful screening of patients with both a prostate-specific antigen (PSA) test and a digital rectal examination, a proportion of patients will still be found to have prostate cancer in the specimen following surgery for benign prostatic hyperplasia (BPH). The likelihood of this happening following complete removal and analysis of the adenoma, such as occurs with open prostatectomy or holmium enucleation of the prostate (HoLEP), appears to be as high as 10% . Adding to this risk is the chance of having cancer diagnosed in the prostate remnant following BPH surgery recently estimated as being 4% during the first 7 yr post-operatively .The two obvious issues that therefore arise are, first, should patients undergoing procedures for BPH such as vaporization techniques, microwave, radiofrequency etc, which do not retrieve tissue for analysis, be counseled regarding this potential for under-diagnosis of prostate cancer? Second, do patients need to be aware of any potentially detrimental aspects of their BPH treatment on subsequent management of prostate cancer, should it be diagnosed?